ID   A-388
AC   CVCL_1063
SY   A388
DR   CLO; CLO_0001584
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7905
DR   BioSample; SAMN03471118
DR   cancercelllines; CVCL_1063
DR   Cell_Model_Passport; SIDM00794
DR   ChEMBL-Cells; CHEMBL3308159
DR   ChEMBL-Targets; CHEMBL2366355
DR   Cosmic; 688037
DR   Cosmic; 910697
DR   Cosmic; 1995333
DR   Cosmic-CLP; 910697
DR   DepMap; ACH-001442
DR   EGA; EGAS00001000978
DR   GDSC; 910697
DR   GEO; GSM1669583
DR   IARC_TP53; 21164
DR   LINCS_LDP; LCL-1342
DR   PharmacoDB; A388_43_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1063
DR   Wikidata; Q54606033
RX   PubMed=327080;
RX   PubMed=375235;
RX   PubMed=833871;
RX   PubMed=1358434;
RX   PubMed=3518877;
RX   PubMed=4357758;
RX   PubMed=6256643;
RX   PubMed=6954533;
RX   PubMed=20164919;
RX   PubMed=22282976;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://www.atcc.org/en/support/technical-support/faqs/morphology-and-growth-of-a388-crl-7905
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg832Cys (c.2494C>T); ClinVar=VCV000936373; Zygosity=Heterozygous (ATCC=CRL-7905; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (ATCC=CRL-7905; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (ATCC=CRL-7905; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=4.06%; Native American=0.32%; East Asian, North=3.84%; East Asian, South=0%; South Asian=0%; European, North=50.76%; European, South=41.03% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; Cosmic-CLP; DepMap
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 28,30
ST   D3S1358: 13
ST   D5S818: 11,13
ST   D7S820: 10
ST   D8S1179: 12,13
ST   FGA: 22
ST   Penta D: 7,10
ST   Penta E: 11,13
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   86Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 35
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1358434;
RA   Conway K., Morgan D., Phillips K.K., Yuspa S.H., Weissman B.E.;
RT   "Tumorigenic suppression of a human cutaneous squamous cell carcinoma
RT   cell line in the nude mouse skin graft assay.";
RL   Cancer Res. 52:6487-6495(1992).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4357758; DOI=10.1093/jnci/51.5.1417;
RA   Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H.,
RA   Dosik H., Parks W.P.;
RT   "In vitro cultivation of human tumors: establishment of cell lines
RT   derived from a series of solid tumors.";
RL   J. Natl. Cancer Inst. 51:1417-1423(1973).
//
RX   PubMed=6256643; DOI=10.1038/288724a0;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.;
RT   "Defective repair of alkylated DNA by human tumour and
RT   SV40-transformed human cell strains.";
RL   Nature 288:724-727(1980).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//